Literature DB >> 2610693

Coomassie Brilliant Blue G is a more potent antagonist of P2 purinergic responses than Reactive Blue 2 (Cibacron Blue 3GA) in rat parotid acinar cells.

S P Soltoff1, M K McMillian, B R Talamo.   

Abstract

The ability of Brilliant Blue G (Coomassie Brilliant Blue G) and Reactive Blue 2 (Cibacron Blue 3GA) to block the effects of extracellular ATP on rat parotid acinar cells was examined by evaluating their effects on ATP-stimulated 45Ca2+ entry and the elevation of [Ca2+]i (Fura 2 fluorescence). ATP (300 microM) increased the rate of Ca2+ entry to more than 25-times the basal rate and elevated [Ca2+]i to levels more than three times the basal value. Brilliant Blue G and Reactive Blue 2 greatly reduced the entry of 45Ca2+ into parotid cells, but the potency of Brilliant Blue G (IC50 approximately 0.4 microM) was about 100-times that of Reactive Blue 2. Fura 2 studies demonstrated that inhibitory concentrations of these compounds did not block the cholinergic response of these cells, thus demonstrating the selectivity of the dye compounds for purinergic receptors. Unlike Reactive Blue 2, effective concentrations of Brilliant Blue G did not substantially quench Fura 2 fluorescence. The greater potency of Brilliant Blue G suggests that it may be very useful in identifying P2-type purinergic receptors, especially in studies which utilize fluorescent probes.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2610693     DOI: 10.1016/0006-291x(89)92741-1

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  22 in total

1.  Functional characterisation of P2 purinoceptors in PC12 cells by measurement of radiolabelled calcium influx.

Authors:  A D Michel; C B Grahames; P P Humphrey
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-11       Impact factor: 3.000

Review 2.  Activation and regulation of purinergic P2X receptor channels.

Authors:  Claudio Coddou; Zonghe Yan; Tomas Obsil; J Pablo Huidobro-Toro; Stanko S Stojilkovic
Journal:  Pharmacol Rev       Date:  2011-07-07       Impact factor: 25.468

Review 3.  P2X receptors as drug targets.

Authors:  R Alan North; Michael F Jarvis
Journal:  Mol Pharmacol       Date:  2012-12-19       Impact factor: 4.436

4.  Bromoenol lactone enhances the permeabilization of rat submandibular acinar cells by P2X7 agonists.

Authors:  N Chaib; E Kabré; E Alzola; S Pochet; J P Dehaye
Journal:  Br J Pharmacol       Date:  2000-02       Impact factor: 8.739

5.  Potentiation by 2,2'-pyridylisatogen tosylate of ATP-responses at a recombinant P2Y1 purinoceptor.

Authors:  B F King; C Dacquet; A U Ziganshin; D F Weetman; G Burnstock; P M Vanhoutte; M Spedding
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

6.  Effects of ATP antagonists on purinoceptor-operated inward currents in rat phaeochromocytoma cells.

Authors:  K Nakazawa; K Inoue; K Fujimori; A Takanaka
Journal:  Pflugers Arch       Date:  1991-04       Impact factor: 3.657

7.  Modulation of extracellular ATP-induced Ca2+ responses: role of protein kinases.

Authors:  L Tenneti; B R Talamo
Journal:  Biochem J       Date:  1993-10-01       Impact factor: 3.857

8.  Evidence for the presence of both pre- and postjunctional P2-purinoceptor subtypes in human isolated urinary bladder.

Authors:  S Palea; C Pietra; D G Trist; W Artibani; A Calpista; M Corsi
Journal:  Br J Pharmacol       Date:  1995-01       Impact factor: 8.739

Review 9.  Recent patents on novel P2X(7) receptor antagonists and their potential for reducing central nervous system inflammation.

Authors:  Scott A Friedle; Marjorie A Curet; Jyoti J Watters
Journal:  Recent Pat CNS Drug Discov       Date:  2010-01

10.  Antagonism by reactive blue 2 but not by brilliant blue G of extracellular ATP-evoked responses in PC12 phaeochromocytoma cells.

Authors:  K Inoue; K Nakazawa; M Ohara-Imaizumi; T Obama; K Fujimori; A Takanaka
Journal:  Br J Pharmacol       Date:  1991-04       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.